SCHEMBL26869

SCHEMBL26869

COc1ccc(C(OC[C@@]23CCO[C@@H]([C@H](n4cc(C)c(=O)[nH]c4=O)O2)[C@@H]3OP(OCCC#N)N(C(C)C)C(C)C)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TK2 O00142 12/20 0.33
TK1 P04183 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7067321 0.94 TK2 (0.34) TK2TK1
SCHEMBL5861676 0.94 TK2 (0.34) TK2TK1
SCHEMBL1099028 0.94 TK2 (0.34) TK2TK1
SCHEMBL5557385 0.94 TK2 (0.34) TK2TK1
SCHEMBL2768845 0.94 TK2 (0.34) TK2TK1
SCHEMBL3842695 0.93 TK2 (0.33) TK2TK1
SCHEMBL4772315 0.91
SCHEMBL4778024 0.89
SCHEMBL13383968 0.88 TK2 (0.32) TK2TK1
SCHEMBL3033795 0.88 TK2 (0.33) TK2TK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1152009-B1 NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES SANKYO CO (JP) 2005-01-26 EP claimed
US-20230348522-A1 METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-11-02 US disclosed
US-9885036-B2 Double-stranded polynucleotide DAIICHI SANKYO COMPANY, LIMITED (JP) 2018-02-06 US disclosed
US-9657049-B2 ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors Matsuo, Masafumi (JP) 2017-05-23 US disclosed
US-9657050-B2 ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors Masafumi, Matsuo (JP) 2017-05-23 US disclosed
EP-2530153-B1 ENA nucleic acid drugs modifying splicing in mRNA precursor MATSUO MASAFUMI (JP) 2016-03-16 EP disclosed
EP-2530154-B1 ENA nucleic acid drugs modifying splicing in mRNA precursor MATSUO MASAFUMI (JP) 2016-03-16 EP disclosed
EP-2386636-B1 ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN MRNA PRECURSOR MATSUO MASAFUMI (JP) 2016-01-27 EP disclosed
US-9243026-B2 ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-26 US disclosed
US-20160002636-A1 ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-07 US disclosed
US-20110152353-A1 DOUBLE-STRANDED POLYNUCLEOTIDE DAIICHI SANKYO COMPANY, LIMITED 2011-06-23 US disclosed
US-7902160-B2 ENA nucleic acid drugs modifying splicing in mRNA precursor Matsuo, Masafumi (JP) 2011-03-08 US disclosed
US-20110046360-A1 ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR Matsuo, Masafumi (JP) 2011-02-24 US disclosed
EP-2135948-A2 ENA nucleic acid drugs modifying splicing in mRNA precursor Matsuo, Masafumi (JP) 2009-12-23 EP disclosed
US-20070117773-A1 Telomerase-inhibiting ENA oligonucleotide SANKYO COMPANY, LIMITED (JP) 2007-05-24 US disclosed
EP-1783216-A1 TELOMERASE-INHIBITORY ENA OLIGONUCLEOTIDE Sankyo Company, Limited (JP) 2007-05-09 EP disclosed
US-20070082861-A1 Ena nucleic acid drugs modifying splicing in mrna precursor MASAFUMI MATSUO (JP) 2007-04-12 US disclosed
US-20060166238-A1 Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same EXIQON A/S (DK) 2006-07-27 US disclosed
EP-1568769-A1 ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR Matsuo, Masafumi (JP) 2005-08-31 EP disclosed
US-20050089889-A1 Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same EXIQON A/S (DK) 2005-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050089889-A1 Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same RNGTT, POLRMT, DNTT TK2 732/4885TK1 537/4885
US-20110152353-A1 DOUBLE-STRANDED POLYNUCLEOTIDE NSUN2, TRDMT1, POLRMT TK2 226/4885TK1 563/4885
US-20070117773-A1 Telomerase-inhibiting ENA oligonucleotide TERT, ENO1, TERB1 TK2 140/4885TK1 192/4885
US-20110046360-A1 ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR SNRPA, RBM17, SNRPA1 TK2 1331/4885TK1 2232/4885
US-20230348522-A1 METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE PFAS, ENPP1, NAAA TK2 941/4885TK1 726/4885
US-20070082861-A1 Ena nucleic acid drugs modifying splicing in mrna precursor SNRPA, RBM17, SNRPA1 TK2 1331/4885TK1 2232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.